LOXL2 and glioma: Using the public databases mentioned above, Kaplan−Meier analysis found that high expression levels of LOXL2 in glioma, LGG, and GBM predicts poor overall survival (Figure 1J–L, Supplementary Figures 1A–H), consistent with the results of previous clinical case studies (24).